SCHEMBL4839490

SCHEMBL4839490

O=C(c1ccc(F)cc1)N1CCc2ccccc2C1CCN1CCC(c2cccc3c2OCC3)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 11/20 0.47
DRD2 P14416 10/20 0.47
DRD3 P35462 10/20 0.47
HTR1A P08908 3/20 0.45
HTR1D P28221 2/20 0.42
HTR1B P28222 2/20 0.42
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
DRD1 P21728 1/20 0.42
DRD4 P21917 1/20 0.42
ADRA1D P25100 1/20 0.42
ADRA1A P35348 1/20 0.42
ADRA1B P35368 1/20 0.42
HTR2B P41595 1/20 0.42
HTR2C P28335 3/20 0.40
CCR3 P51677 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4837834 0.85 HTR1D (0.41) HTR2ADRD2DRD3HTR1AHTR1D
SCHEMBL4837767 0.85 DRD2 (0.54) DRD2HTR1AHTR2C
SCHEMBL4836909 0.83 NPSR1 (0.49) HTR2ADRD2DRD3HTR1AHTR1D
SCHEMBL4838989 0.83 DRD2 (0.46) HTR2ADRD2DRD3HTR1ADRD4
SCHEMBL4830065 0.82 NPSR1 (0.51) HTR2ADRD2DRD3HTR1AHTR1D
SCHEMBL4839787 0.82 HTR2A (0.47) HTR2ADRD2DRD3
SCHEMBL4841563 0.81 DRD2 (0.54) HTR2ADRD2DRD3HTR1ADRD1
SCHEMBL4837162 0.81 DRD2 (0.40) HTR2ADRD2DRD3HTR1AHTR1D
SCHEMBL4837310 0.80 DRD2 (0.48) DRD2DRD4
SCHEMBL4833070 0.79 MCHR1 (0.45) HTR2ADRD2DRD3HTR1AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 HTR2A 894/4885DRD2 684/4885DRD3 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.